Nonalcoholic fatty liver disease is a growing epidemic affecting 30% of the adult population in the Western world. Its progressive form, nonalcoholic steatohepatitis (NASH), is associated with an increased risk of advanced fibrosis, cirrhosis and liver-related mortality. Therefore, the detection of NAFLD and risk stratification according to the severity of the disease is crucial for the management of patients with NAFLD. Liver biopsy for such risk stratification strategies is limited by its cost and risks; therefore, noninvasive alternatives have been developed. Among noninvasive biomarkers developed in NAFLD, magnetic resonance (MR)-based biomarkers have emerged as key noninvasive biomarkers in NAFLD with the ability to accurately detect hepatic steatosis and liver fibrosis. The potential utility of MRI for the detection of NASH and functional liver assessment has also recently emerged. In the current review, we will discuss the data supporting the utility of MR-based biomarker for the detection of features of NAFLD and its potential use in clinical practice and clinical research in NAFLD.? 2020 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.
展开▼
机译：非酒精性脂肪肝病是一种越来越多的疫情，影响西方世界的成年人口的30％。其逐步形式，非酒精性脂肪肝炎（NASH）与纤维化，肝硬化和肝脏相关死亡率的风险增加有关。因此，根据疾病的严重程度检测NAFLD和风险分层对NAFLD患者的管理至关重要。这种风险分层策略的肝活检受其成本和风险的限制;因此，已经开发出非侵入性替代品。在NAFLD开发的非侵入性生物标志物中，基于磁共振（MR）的生物标志物已成为NAFLD中的关键非侵入性生物标志物，具有准确地检测肝脏脂肪变性和肝纤维化的能力。最近也出现了MRI用于检测纳什和功能性肝脏评估的潜在效用。在目前的审查中，我们将讨论支持基于MR的生物标志物的实用性，以检测NAFLD的特征及其在NAFLD临床实践和临床研究中的潜在用途。 2020作者。 John Wiley＆Sons Ltd.出版的内分泌，糖尿病和新陈代谢
展开▼
